Avenue Therapeutics gets complete response letter from USFDA for IV Tramadol EP News Bureau Jun 15, 2021 The CRL stated that the delayed and unpredictable onset of analgesia with IV tramadol does not support its benefit as a…
Avenue Therapeutics receives complete response letter from the FDA for IV Tramadol EP News Bureau Oct 12, 2020 The CRL stated that IV tramadol, intended to treat patients in acute pain who require an opioid, is not safe for the intended…
